Reshape Lifesciences Inc (RSLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2005 | |
| Cash Flows From Operating Activities | |
| Net Income | -11,215 |
| Depreciation Amortization | 143 |
| Accounts payable and accrued liabilities | 159 |
| Other Working Capital | 769 |
| Other Operating Activity | -134 |
| Operating Cash Flow | $-10,278 |
| Cash Flows From Investing Activities | |
| PPE Investments | -450 |
| Investing Cash Flow | $-450 |
| Cash Flows From Financing Activities | |
| Change In Short Term Borrowing | 8,376 |
| Common Stock Issued | 29 |
| Other Financing Activity | 7,710 |
| Financing Cash Flow | $16,115 |
| Beginning Cash Position | 5,332 |
| End Cash Position | 10,719 |
| Net Cash Flow | $5,387 |
| Free Cash Flow | |
| Operating Cash Flow | -10,278 |
| Capital Expenditure | -450 |
| Free Cash Flow | -10,728 |